All In Biotech

Investigational drug · Phase 3

Zola-cel

Also called: BMS-986353, CC-97540

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

3

Any phase or sponsor naming "Zola-cel"

First trial start

2025

Jul 14, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Zola-cel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Systemic Sclerosis
  • Lupus Erythematosus, Systemic
  • Lupus Nephritis
  • Chronic Immune Thrombocytopenia
  • Autoimmune Hemolytic Anemia

Approved drugs for the same conditions: Anemia · Immune thrombocytopenia · Lupus (SLE) · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Zola-cel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Systemic Sclerosis

  • AZD0120GC012FPhase 39 trials

    AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis

  • Rese-celCABA-201Phase 34 trials

    Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma

  • ABBV-722Phase 32 trials

    AbbVie · Rheumatoid Arthritis, Systemic Sclerosis

  • UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials

    Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1

  • NKX019Phase 22 trials

    Nkarta, Inc. · Lupus Nephritis, Primary Membranous Nephropathy, Systemic Sclerosis

  • L608Phase 21 trial

    Pharmosa Biopharm Inc. · Systemic Sclerosis

  • PF-08154225Phase 21 trial

    Pfizer · Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.